Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S1-221
- Development stage
- Phase 3
- Lead developer
- Delphian Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
S1-221 is an investigational oral liquid **cannabinoid combination** developed by Delphian Therapeutics for the acute treatment of migraine. It contains cannabidiol and delta-9-tetrahydrocannabinol and has been evaluated in a first-in-human Phase 1 single-ascending-dose study in healthy adults to characterize safety, tolerability, pharmacokinetics, acute subjective effects, and exploratory effects on plasma endocannabinoid levels. Dose selection from this study is intended to support subsequent migraine efficacy studies.
- Other names
- CBD + THCcannabidiol + delta-9-tetrahydrocannabinol
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on S1-221.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S1-221.